Results 21 to 30 of about 983,540 (218)

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents [PDF]

Human Vaccines & Immunotherapeutics
Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12–17 years), with and without pre-booster SARS-CoV-2 infection.
Amparo L. Figueroa, Kashif Ali, Gary Berman, Wenqin Xu, Weiping Deng, Bethany Girard, Anne Yeakey, Karen Slobod, Jacqueline Miller, Rituparna Das, Frances Priddy   +10 more
doaj   +2 more sources

mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions

Science Translational Medicine, 2022
The successful development of several coronavirus disease 2019 (COVID-19) vaccines has substantially reduced morbidity and mortality in regions of the world where the vaccines have been deployed.
Paulina Kapłonek, Deniz Cizmeci, Stephanie Fischinger, Ai‐ris Y. Collier, Todd J. Suscovich, Caitlyn Linde, Thomas Broge, Colin Mann, Fatima Amanat, Diana Dayal, Justin Rhee, Michael de St. Aubin, Eric J. Nilles, Elon R. Musk, Anil Menon, Erica Ollmann Saphire, Florian Krammer, Douglas A. Lauffenburger, Dan H. Barouch, Galit Alter   +19 more
openalex   +3 more sources

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273 [PDF]

Journal of the American Medical Association (JAMA), 2021
Methods | Healthcareworkersatatertiarycarecenter(Ziekenhuis Oost-Limburg, Belgium) who were scheduled for vaccination with 2 doses of either mRNA-1273 or BNT162b2 were invited to participate in this prospective cohort.
Deborah Steensels, Noëlla Pierlet, Joris Penders, Dieter Mesotten, Line Heylen   +4 more
openalex   +2 more sources

Reply to the letter from Dr. Nikolayevskyy et al. referring to our publication published in the Journal of Virological Methods 298 (2021)11:4295 “Evaluation of the QuantiFERON SARS-CoV-2 Interferon-ɣ release assay in mRNA-1273 vaccinated health care workers”

Journal of Virological Methods, 2022
we evaluated a novel assay from Qiagen measuring T-cell responses to two SARS-CoV-2 peptide antigen pools (antigen pool 1 and antigen pool 2) in healthy probands vaccinated twice with the Moderna vaccine mRNA-1723 against SARS-CoV-2.We reported that only
Alex Krüttgen, M. Kleines
semanticscholar   +1 more source

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

New England Journal of Medicine, 2021
* Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).
N. Doria-Rose, M. Suthar, M. Makowski, S. O'connell, A. McDermott, B. Flach, J. Ledgerwood, J. Mascola, B. Graham, Bob C. Lin, S. O'Dell, S. Schmidt, A. Widge, V. Edara, E. Anderson, L. Lai, K. Floyd, N. Rouphael, V. Zarnitsyna, P. Roberts, M. Makhene, Wendy L. Buchanan, C. Luke, J. Beigel, L. Jackson, K. Neuzil, H. Bennett, B. Leav, J. Albert, Pratap Kunwar   +29 more
semanticscholar   +1 more source

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

Nature Communications, 2023
We previously presented day 29 interim safety and immunogenicity results from a phase 2/3 study (NCT04927065) comparing the Omicron-BA.1-containing bivalent vaccine mRNA-1273.214 (50-µg) to the 50-µg mRNA-1273 booster in adults who previously received ...
Spyros Chalkias, Charles Harper, Keith Vrbicky, Stephen R. Walsh, Brandon Essink, Adam Brosz, Nichole McGhee, Joanne E. Tomassini, Xing Chen, Ying Chang, Andrea Sutherland, David C. Montefiori, Bethany Girard, Darin K. Edwards, Jing Feng, Honghong Zhou, Lindsey R. Baden, Jacqueline M. Miller, Rituparna Das   +18 more
doaj   +1 more source

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination

Journal of the Formosan Medical Association, 2022
Background/Purpose: Efficacy and safety data of heterologous prime-boost vaccination against SARS-CoV-2 remains limited. Methods: We recruited adult volunteers for homologous or heterologous prime-boost vaccinations with adenoviral (ChAdOx1, AstraZeneca)
Wang-Huei Sheng, Sui-Yuan Chang, Pin-Hung Lin, Ming-Ju Hsieh, Hao-Hsiang Chang, Chien-Yu Cheng, Hung-Chih Yang, Ching-Fu Pan, Si-Man Ieong, Tai-Ling Chao, Jang-Pin Chen, Shu-Hsing Cheng, Shan-Chwen Chang   +12 more
doaj   +1 more source

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

Nature Medicine, 2022
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant is highly transmissible with potential immune escape. We conducted a test-negative case–control study to evaluate mRNA-1273 vaccine effectiveness (VE) against ...
H. Tseng, B. Ackerson, Yi Luo, L. Sy, C. Talarico, Yun Tian, K. Bruxvoort, J. Tubert, A. Florea, J. Ku, Gina S. Lee, S. Choi, H. Takhar, Michael Aragones, L. Qian   +14 more
semanticscholar   +1 more source

Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination

Clinical Case Reports, 2022
In this case report, we presented a case of myocarditis as a rare complication that developed after Covid mRNA‐1273 vaccine. Cases of post‐vaccine myocarditis usually progress with mild symptoms.
Suresh Babu Chellapandian, Suha Turkmen, Imtiaz Salim, Shanmugavel Chinnakaruppan, Jassim Mohammad   +4 more
doaj   +1 more source

Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework [PDF]

Infectious Disease and Therapy
INTRODUCTION:The mRNA vaccines mRNA-1273 and BNT162b2 demonstrated high efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in phase 3 clinical trials, including among older adults.
Bausch-Jurken, MT, Beck, E, Green, N, Haeussler, K, Kavikondala, S, Malmenäs, M, Mishra, NK, Nassim, M, Sharma, P, Van de Velde, N, Wang, X   +10 more
core   +2 more sources